Albuterol (Ventolin)

Emergency & Prehospital

• Acute asthma exacerbation: start here at every severity. For moderate to severe attacks, add ipratropium
• Chronic obstructive pulmonary disease (COPD) exacerbation: start with a bronchodilator. A short-acting anticholinergic can join it or stay out
• Bronchospasm with anaphylaxis: the adjunct for bronchospasm only, and only after IM epinephrine (GINA 2026; NASEMSO v3.0, Anaphylaxis, p. 66). It does not treat airway edema or shock.
• Other reversible bronchospasm: labeled for reversible obstructive airway disease in adults and children

ED / ICU / Transport

• Severe or life-threatening asthma: keep nebulizing, repeated or continuous, while systemic corticosteroids and IV magnesium get to work
• Hyperkalemia (off-label): This buys time. Albuterol shifts K⁺ into the cells. It does not remove K⁺. It works best paired with IV insulin and glucose, since the pair lowers K⁺ more than insulin alone, so use that pairing wherever you can. The UK Kidney Association recommends it at K⁺ ≥6.5 mEq/L and calls it optional at 6.0–6.4. It advises against albuterol alone in severe hyperkalemia, because response varies. Up to 40% of patients with end-stage renal disease do not respond. No insulin-glucose? Albuterol is only a bridge. Arrange K⁺ removal.
• Hyperkalemic cardiac arrest: AHA 2025 Part 10 rates inhaled β2-agonists COR 3: No Benefit (C-EO). Keep albuterol out of arrest care.

Other Uses

• Prevention of exercise-induced bronchospasm: labeled for age 4 yr and older
• As-needed reliever in chronic asthma or COPD: the Global Initiative for Asthma (GINA) no longer recommends SABA-only asthma treatment without an inhaled corticosteroid (ICS). Discharge asthma patients on an ICS-containing regimen. Never SABA alone.
• Alternatives to SABA-only relief: GINA 2026 adds ICS-formoterol as an option to SABA for mild exacerbations (age 6 yr and older). It also lists as-needed budesonide-albuterol (Airsupra, adults) as an anti-inflammatory reliever. The US 2020 NAEPP updates endorse ICS-formoterol single-inhaler therapy and as-needed ICS with SABA.

Available Forms

• Nebulizer solution 0.083%: 2.5 mg/3 mL unit-dose vial. Ready to use, no dilution. Labeled for age 2 yr and older weighing ≥15 kg.
• Nebulizer concentrate 0.5%: 5 mg/mL. The 2.5 mg/0.5 mL vial is diluted to 3 mL with sterile saline, and it is the one for continuous nebulization. The unit-dose vial is labeled for age 12 yr and older. Pediatric weight-based use (EPR-3 continuous dose) is off-label.
• Low-strength nebulizer solution: 0.63 mg/3 mL (0.021%) and 1.25 mg/3 mL (0.042%). Labeled for relief of bronchospasm in children 2–12 yr (3–4 times daily). They were not studied in acute attacks (label), so use 2.5 mg for exacerbations.
• Metered-dose inhaler (MDI), HFA: 90 mcg albuterol (108 mcg albuterol sulfate) per actuation; 60- or 200-actuation canisters with a dose counter.
• Dry-powder inhaler (DPI): 90 mcg per inhalation (ProAir RespiClick, Digihaler). It is breath-actuated and contains lactose. Age 4 yr and older: 2 inhalations every 4–6 hr. For exercise-induced bronchospasm, take 2 inhalations 15–30 min before exercise. There is no priming. Don't use a spacer or holding chamber with it.
• Oral: 2 mg and 4 mg tablets, and syrup 2 mg/5 mL. It's too slow for acute bronchospasm.
• Combinations: ipratropium-albuterol nebulizer solution (DuoNeb): 0.5 mg ipratropium and 2.5 mg albuterol (as 3 mg albuterol sulfate) in 3 mL; Combivent Respimat (ipratropium-albuterol); Airsupra (albuterol-budesonide).

Adult Dosing

Pediatric Dosing

Pediatric doses come from AHA/AAP 2025 when that source states a dose. Next comes the NASEMSO National Model EMS Clinical Guidelines v3.0 (2022), then the US label. If none of them gives a dose, this page shows none. A pediatric maximum never goes above the adult maximum dose (NASEMSO Universal Care Guideline, p. 13). Unless a dose is marked labeled, treat it as off-label. Check your weight math here: pediatric weight-based dosing.

Preparation & Administration

• MDI check: Read the dose counter (discard at 000). Prime if new, unused for more than 2 weeks or dropped (Ventolin HFA: 4 sprays, shaking before each).
• MDI with spacer: Shake before every puff and give one puff at a time into the spacer, with 5–6 breaths after each, per GINA 2026; follow the spacer's instructions for use.
• Mask or mouthpiece: Face mask for children 0–3 yr; switch to a mouthpiece as soon as the child can use it, per GINA 2026. Some spacers need a detergent wash (without rinsing) or 2–4 priming puffs to reduce static, per GINA 2026.
• Nebulizer: Use the whole 3 mL unit-dose vial (2.5 mg of 0.083%) (label). In COPD, drive it with air. GOLD 2026 notes oxygen-driven nebulization can raise PaCO₂. In children with low saturation, an oxygen-driven nebulizer may be used, per GINA 2026.
• Continuous nebulization: Large-volume nebulizer; document the hourly dose.
• Intubated or ventilated patient (MDI in-line): Place a spacer or chamber adapter in the inspiratory limb and leave it in the circuit. Shake the MDI, remove the heat and moisture exchanger (HME) during delivery and do not change ventilator settings. Actuate at the onset of inspiration and repeat every 20–30 s until the dose is given. Start with 4–6 puffs. Titrate to response: a falling peak-to-plateau pressure gap, less auto-PEEP, better expiratory flow. Repeat every 3–4 hr, sooner in status asthmaticus. Continuous in-line nebulizer flow can cause missed triggers and hypoventilation that ventilator alarms may not catch. Watch the delivered tidal volumes. Bag-ventilated patients: in-line adapter per agency protocol. Follow agency or respiratory therapy protocol.

Contraindications

• Hypersensitivity to albuterol or any product component
• DPI products (ProAir RespiClick, Digihaler): severe milk-protein hypersensitivity (lactose carrier)

Precautions

• Cardiovascular disease: coronary insufficiency, arrhythmia, hypertension. Here's what β-agonists do to the tracing: they can flatten T waves, prolong QTc and depress ST segments.
• Seizure disorder, hyperthyroidism, diabetes: The response is exaggerated. Large IV doses have worsened diabetes and ketoacidosis.
• Rising use: needing more doses than usual means the asthma is getting worse. Reassess, and treat the inflammation. Excessive use of inhaled sympathomimetics has been fatal.
• Labor: It may relax the uterus. It isn't approved for preterm labor, where pulmonary edema has been reported with β2-agonist tocolysis.
• Hypokalemia risk: loop or thiazide diuretics, high or continuous doses, hypoxia.

Hold / Reassess If

• Wheeze or dyspnea worsens right after a dose. Suspect paradoxical bronchospasm. Stop, and switch therapy
• New chest pain, ischemic ST change or new tachyarrhythmia: stop dosing, 12-lead ECG
• Lactate rising, or breathing faster while air entry improves? Consider β-agonist toxicity before giving more
• Hyperkalemia with ischemic heart disease: limit the dose to 10 mg with cardiac monitoring

Common

• Tremor: about 20% with nebulized doses
• Throat irritation: about 10% with MDI; cough about 5%
• Dizziness: about 7%; nervousness and nausea about 4%; headache about 3%
• Tachycardia, palpitations: dose-related

Serious / Life-Threatening

Overdose & Toxicity Management

• Signs: tachycardia, arrhythmia, angina, hypertension or hypotension, tremor, seizures, hypokalemia, hyperglycemia, metabolic acidosis; cardiac arrest has occurred.
• Immediate management: stop albuterol; continuous ECG; check K⁺, glucose and a blood gas with lactate; symptomatic care.
• Antidote: none. Give supportive care and treat the complications. The label says a cardioselective β-blocker may be considered, keeping in mind that it can cause bronchospasm (HFA label, Overdosage).

Clinically Significant Interactions

Nebulizer Compatibility

• Inhaled drug, so IV compatibility doesn't apply.
• It may be mixed with ipratropium nebulizer solution in the same cup.
• Other nebulized drugs have no established compatibility. Give them separately.
• Verify with an institutional compatibility resource.

• Pediatrics: MDI labeled from 4 yr. Nebulizer solution 0.083% and low-strength vials from 2 yr. The 0.5% unit-dose vial from 12 yr (pediatric weight-based use is off-label). Guidelines still use a spacer and mask in younger children with acute asthma. Don't give it in bronchiolitis. The doses are in the Pediatric Dosing table.
• Neonates: Not established. Neonatal hyperkalemia use belongs to the specialist.
• Pregnancy: Human data have not consistently shown a risk of birth defects or miscarriage with inhaled albuterol. Cleft palate showed up in mice. Poorly controlled asthma raises the risk of preeclampsia, prematurity and low birth weight. So treat exacerbations fully.
• Lactation: There are no human milk data. Plasma levels after inhaled doses are low, so milk levels are likely low too. Don't withhold treatment.
• Older Adults: Start at the low end. Cardiac disease and interacting drugs are common in this group.
• Renal Impairment: The label gives no adjustment for inhaled albuterol. The absorbed drug and its metabolite leave the body mainly in urine. Racemic albuterol clearance fell 67% in renal impairment (CrCl 7–53 mL/min). Use caution with high doses, such as 10–20 mg for hyperkalemia, and monitor HR, rhythm and K⁺. Up to 40% of patients with end-stage renal disease (ESRD) do not lower K⁺ with albuterol.
• Hepatic Impairment: No specific adjustment established.
• Obesity / Dosing Weight: Adult doses are fixed. A pediatric dose never goes above the adult maximum. The only weight-based pediatric dose on this page is the continuous 0.5 mg/kg/hr (EPR-3).
• Hypercapnic COPD: Drive nebulizers with air, and give titrated oxygen separately. In COPD or any other risk of hypercapnic failure, target 88 to 92% until you have a blood gas.

• Scope: EMT through critical-care transport give or assist with albuterol. It varies by state and agency protocol.
• Storage & Stability: Keep the MDI at 20–25°C (68–77°F). Excursions to 15–30°C (59–86°F) are allowed. Canisters can burst above 49°C (120°F), so don't leave them on a hot dash. Nebulizer vials go at 2–25°C (36–77°F) in the foil pouch, protected from light.
• Carried Concentration: 0.083% (2.5 mg in 3 mL, ready to use) and 0.5% (2.5 mg in 0.5 mL, dilute first) give the same dose in very different volumes. Read the label before you draw up continuous or off-label doses.
• Device Choice: An MDI with spacer works as well as a nebulizer when technique is coached (EPR-3). GINA 2026 prefers the spacer if the patient can use it. If they can't, use a nebulizer. Nebulizers can transmit respiratory viral particles at least 1 m, per GINA 2026. Where infection risk matters, prefer the spacer.
• Altitude / Environment: Set the oxygen saturation target for altitude, per GINA 2026.
• Continuous Nebulization in Transport: Confirm the hourly dose, remaining volume for the trip, ECG monitoring and last K⁺.
• Ventilated Patients: Give MDI puffs through an in-line spacer in the inspiratory limb (Preparation & Administration). If a continuous in-line nebulizer is running, watch the delivered volumes.
• Handoff Essentials: total albuterol given (mg or puffs) and times, ipratropium, magnesium, steroid and epinephrine doses, response (work of breathing, SpO₂, PEF), HR trend.

Mechanism of Action

• β2-receptor agonist → adenylyl cyclase → more cyclic AMP → airway smooth-muscle relaxation from trachea to terminal bronchioles. The trigger doesn't matter.
• Cyclic AMP also inhibits mediator release from airway mast cells.
• Na⁺/K⁺-ATPase stimulation → K⁺ shifts into cells (therapeutic in hyperkalemia, adverse in asthma).
• β2 receptors make up 10–50% of cardiac β-receptors. Even a selective agonist causes tachycardia.

Pharmacokinetics

• Half-life: about 4.6 hr after inhalation; 5–6 hr after oral dosing.
• Absorption: Less than 20% of a nebulized dose is absorbed. The rest stays in the device or gets exhaled.
• Protein binding: low (about 10%).
• Metabolism: sulfation, mainly by the sulfotransferase SULT1A3. Swallowed drug is largely metabolized in the gut. After an oral dose, about 60% of the drug recovered in urine is metabolite.
• Elimination: renal, 80–100% as parent drug or its primary metabolite, most within 24 hr; less than 20% in feces.
• Stereochemistry: It is racemic. The R-enantiomer (levalbuterol) carries the bronchodilator activity.

Generic Name

Albuterol sulfate (international name: salbutamol)

Brand Names

Ventolin HFA; ProAir RespiClick and ProAir Digihaler (DPI); Proventil HFA and ProAir HFA (older MDI brands); combinations: Combivent Respimat (ipratropium-albuterol), Airsupra (albuterol-budesonide, as-needed reliever for adults)

Pharmacologic Class

Short-acting β2-adrenergic agonist (SABA)

Therapeutic Class

Bronchodilator; potassium-shifting adjunct (off-label)

Controlled Substance

Not controlled

ISMP High-Alert

No

Look-Alike / Sound-Alike

None on the ISMP confused-names list; the risk is concentration: 0.083% (2.5 mg/3 mL) vs 0.5% (2.5 mg/0.5 mL)